Graybill Wealth Management LTD. Acquires 315 Shares of Becton, Dickinson and Company (NYSE:BDX)

Graybill Wealth Management LTD. boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 1.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,685 shares of the medical instruments supplier’s stock after acquiring an additional 315 shares during the period. Graybill Wealth Management LTD.’s holdings in Becton, Dickinson and Company were worth $4,129,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of BDX. Ontario Teachers Pension Plan Board lifted its stake in shares of Becton, Dickinson and Company by 3.8% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock worth $451,641,000 after buying an additional 68,509 shares in the last quarter. Sapient Capital LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at $1,295,000. Vest Financial LLC raised its stake in shares of Becton, Dickinson and Company by 27.5% in the fourth quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after purchasing an additional 22,207 shares during the last quarter. Caden Capital Partners LP lifted its holdings in shares of Becton, Dickinson and Company by 26.7% during the fourth quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after purchasing an additional 17,599 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock worth $3,685,000 after buying an additional 6,190 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on BDX shares. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Barclays lifted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $280.17.

View Our Latest Stock Analysis on BDX

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded down $1.08 during mid-day trading on Thursday, reaching $230.54. 499,689 shares of the company’s stock traded hands, compared to its average volume of 1,438,080. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The firm has a market capitalization of $66.63 billion, a PE ratio of 50.82, a price-to-earnings-growth ratio of 2.05 and a beta of 0.44. Becton, Dickinson and Company has a 12 month low of $224.00 and a 12 month high of $287.32. The firm has a 50 day moving average price of $234.42 and a two-hundred day moving average price of $237.88.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the previous year, the company posted $2.86 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, research analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.65%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares of the company’s stock, valued at $3,457,713.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,615 shares of company stock worth $2,033,381. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.